Plazomicin Injection
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease
Conditions
End Stage Renal Disease
Trial Timeline
Jan 5, 2021 → Jun 9, 2021
NCT ID
NCT04699656About Plazomicin Injection
Plazomicin Injection is a phase 1 stage product being developed by Cipla for End Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04699656. Target conditions include End Stage Renal Disease.
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Disease were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04699656 | Phase 1 | Completed |
Competing Products
20 competing products in End Stage Renal Disease